Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth

Cancer Research

Volumn 73, Issue 2, 2013, Pages 792-803

  Burns, Sarah S ^a,b   Akhmametyeva, Elena M ^a,b   Oblinger, Janet L ^a,b   Bush, Matthew L ^b,e   Huang, Jie ^a,b   Senner, Volker ^d   Chen, Ching Shih ^c   Jacob, Abraham ^b,f   Welling, D Bradley ^b   Chang, Long Sheng ^a,b  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY OF KENTUCKY   (United States)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AR 12; AR 42; AURORA A KINASE; AURORA B KINASE; BIM PROTEIN; CYCLIN A; CYCLIN B; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; CYCLINE; HISTONE DEACETYLASE INHIBITOR; MERLIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 INHIBITOR; PROTEIN BCL XL; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EXON; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; HUMAN; HUMAN CELL; IN VIVO STUDY; MENINGIOMA; MENINX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENES, NEUROFIBROMATOSIS 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; MENINGEAL NEOPLASMS; MENINGES; MENINGIOMA; MICE; MICE, SCID; PHENYLBUTYRATES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872559874     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1888     Document Type: Article

References (50)

1. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol 2010;99: 307-14.
2. Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol 2010;99: 341-7.
3. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363: 515-21.
4. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72: 791-800.
5. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer- Rachamimov AO, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 2009;29: 4250-61.
6. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002;16: 1060-5.
7. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, Chareyre F, Taranchon E, Han ZY, et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 2011;30: 2333-44.
8. Lee WH. Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery 1990;27: 389-95.
9. Tanaka K, Sato C, Maeda Y, Koike M, Matsutani M, Yamada K, et al. Establishment of a human malignant meningioma cell line with amplified c-myc oncogene. Cancer 1989;64: 2243-9.
10. Ragel BT, Elam IL, Gillespie DL, Flynn JR, Kelly DA, Mabey D, et al. A novel model of intracranial meningioma in mice using luciferaseexpressing meningioma cells. J Neurosurg 2008;108: 304-10.
11. McCutcheon IE, Friend KE, Gerdes TM, Zhang BM, Wildrick DM, Fuller GN. Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth. J Neurosurg 2000;92: 306-14.
12. Baia GS, Dinca EB, Ozawa T, Kimura ET, McDermott MW, James CD, et al. An orthotopic skull base model of malignant meningioma. Brain Pathol 2008;18: 172-9.
13. Cargioli TG, Ugur HC, Ramakrishna N, Chan J, Black PM, Carroll RS. Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery 2007;60: 750-9.
14. Baia GS, Slocum AL, Hyer JD, Misra A, Sehati N, VandenBerg SR, et al. A genetic strategy to overcome the senescence of primary meningioma cell cultures. J Neurooncol 2006;78: 113-21.
15. Püttmann S, Senner V, Braune V, Hillmann B, Exeler R, Rickert C, et al. Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest 2005;85: 1163-71.
16. Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt- DeMasters BK, Brown HG, et al. Molecular characterization of human meningiomas by gene expression profiling using high density oligonucleotide microarrays. Am J Pathol 2002;161: 665-72.
17. Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS. cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 2002; 23: 736-48.
18. Cuevas IC, Slocum AL, Jun P, Costello JF, Bollen AW, Riggins GJ, et al. Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 2005;65: 5070-5.
19. Hanemann CO, Bartelt-Kirbach B, Diebold R, Kämpchen K, Langmesser S, Utermark T. Differential gene expression between human schwannoma and control Schwann cells. Neuropathol Appl Neurobiol 2006;32: 605e14.
20. Jacob A, Lee TX, Neff BA, Miller S, Welling B, Chang L-S. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma. Otol Neurotol 2008;29: 58-68.
21. Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen C-S, et al. Growth inhibitory and anti-tumor activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer 2009;45: 1709-20.
22. Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol 2011;13: 983-99.
23. Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Ray-Chaudhury A, et al. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope 2012;122: 174-89.
24. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6: 38-51.
25. ChenCS, Weng SC, Tseng PH, Lin HP, Chen C-S. Histone acetylationindependent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 2005; 280: 38879-87.
26. Chang L-S, Jacob A, Lorenz M, Rock J, Akhmametyeva EM, Mihai G, et al. Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice. Laryngoscope 2006;116: 2018-26.
27. Chang L-S, Welling DB. Molecular biology of vestibular schwannomas. Methods Mol Biol 2009;493: 163-77.
28. Fields RD, Lancaster MV. Dual attribute continuous monitoring of cell proliferation/cytotoxicity. Am Biotechnol Lab 1993;11: 48-50.
29. Darzynkiewicz Z, Juan G. DNA content measurement for DNA ploidy and cell cycle analysis. In Current protocols in flow. Somerset, NJ: John Wiley & Sons, Inc.; 1997. Unit 7.5.
30. Chang L-S, Akhmametyeva EM, Wu Y, Zhu L, Welling DB. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics 2002;79: 63-76.
31. Seilly DJ. A chemical test to determine the end point of EDTA decalcification. Med Lab Sci 1982;39: 71-3.
32. Yang YT, Balch C, Kulp SK, Mand MR, Nephew KP, Chen CS. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia 2009;11: 552-63.
33. Hochegger H, Takeda S, Hunt T. Cyclin-dependent kinases and cellcycle transitions: does one fit all. Nat Rev Mol Cell Biol 2008;9: 910-6.
34. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5: 773-85.
35. Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)- HDAC-42, in prostate cancer. Clin Cancer Res 2006;12: 5199-206.
36. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 2007;46: 1119-30.
37. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide- dependent protein kinase-1 inhibitors. Cancer Res 2004;64: 4309-18.
38. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13: 1501-12.
39. Mork CN, Faller DV, Spanjaard RA. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des 2005;11: 1091-104.
40. Nair AR, Boersma LJ, Schiltz L, Chaudhry MA, Muschel RJ. Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. Cancer Lett 2001;166: 55-64.
41. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 1999;274: 34940-47.
42. Mateo F, Vidal-Laliena M, Canela N, Busino L, Martinez-Balbas MA, Pagano M, et al. Degradation of cyclin A is regulated by acetylation. Oncogene 2009;28: 2654-66.
43. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4: 927-36.
44. Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J, et al. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev 2006;20: 2566-79.
45. Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, et al. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 2009;15: 840-50.
46. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005;102: 16090-95.
47. Puaux AL, Ong LC, Jin Y, Teh I, Hong M, Chow PK, et al. A comparison of imaging techniques to monitor tumor growth and cancer progression in living animals. Int J Mol Imaging 2011; e321538.
48. Nakano T, Asano K, Miura H, Itoh S, Suzuki S. Meningiomas with brain edema: radiological characteristics on MRI and review of the literature. Clin Imaging 2002;26: 243-9.
49. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5: 769-84.
50. Sargeant AM, Rengel RC, Kulp SK, Klein RD, Clinton SK, Wang YC, et al. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008;68: 3999-4009.